Drug pricing
Featured Topics
Lead story
Other featured articles
-
U.S. Consumers Overpay for Generic Drugs
Tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, are costing patients, employers and the government billions for what should be inexpensive medicines.
Posted in -
Comments to the Federal Trade Commission on Pharmacy Benefit Managers
Researchers at the USC Schaeffer Center have been studying the pharmaceutical distribution system since 2016; these comments about PBMs draw on that body of research.
Posted in -
Messages in Prescription Drug Advertising for Four Chronic Diseases, 2003-2016: A Content Analysis
Examining the frequency and content of messages related to pharmacological and evidence-based, non-pharmaceutical treatments in direct-to-consumer advertising (DTCA) for prescription drugs treating four chronic diseases in the United States.
Posted in -
Who Is Really Driving Up Insulin Costs?
In the long term, capping insulin payments at $35 a month is just shuffling the deck rather than changing the game of insulin costs.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Drug pricing
Our Work In Drug pricing
-
Pharmacy Switching in Response to Preferred Pharmacy Networks in Medicare Part D
Researchers evaluate the effects of preferred pharmacy networks—a tool that Medicare Part D plans have recently adopted to steer patients to lower cost pharmacies—on the use of preferred pharmacies and factors underlying beneficiaries’ decisions on whether to switch to preferred pharmacies.
Categorized in -
New Evidence Suggests a Lack of Cost-Shifting in Prescription Drug Markets
Recent legislative efforts to regulate drug prices have reignited debates about the interaction between price setting in public insurance programs and commercial market spending.
Categorized in -
The Price of Insulin, Explained
This animation explains research by Schaeffer Center experts that offers one of the most comprehensive looks at the insulin distribution chain and shows which players are profiting, and by how much, from selling insulin.
Categorized in -
Middlemen, Not Drug Companies, Are Pushing Up Insulin Prices, and Congress Doesn’t Have the Right Plan to Fight Back
Congress should take advantage of the current political climate and start reining in the intermediaries in the drug distribution system.
Categorized in -
How Did the Public U.S. Drugmakers’ Sales, Expenses and Profits Change Over Time?
Understanding what drives pharmaceutical firms’ revenue growth is critical to developing evidence-based policies that curb drug costs without reducing the industry’s innovations.
Categorized in -
Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018
Recent US media and policy attention on insulin affordability has focused on the role of manufacturers in setting prices; however, the role of other drug distribution intermediaries in determining prices has received less attention.
Categorized in